List of Tekamlo drug patents

Tekamlo is owned by Novartis.

Tekamlo contains Aliskiren Hemifumarate; Amlodipine Besylate.

Tekamlo has a total of 1 drug patent out of which 0 drug patents have expired.

Tekamlo was authorised for market use on 26 August, 2010.

Tekamlo is available in tablet;oral dosage forms.

The generics of Tekamlo are possible to be released after 21 December, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8613949 NOVARTIS Galenical formulations of organic compounds
Dec, 2029

(6 years from now)

Drugs and Companies using ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE ingredient

Market Authorisation Date: 26 August, 2010

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic